Biolase, Inc. (NASDAQ:BIOL) major shareholder Larry N. Feinberg acquired 12,545,615 shares of the business’s stock in a transaction on Tuesday, December 5th. The shares were bought at an average cost of $0.43 per share, for a total transaction of $5,394,614.45. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Biolase, Inc. (BIOL) traded up $0.05 during mid-day trading on Friday, reaching $0.45. 706,700 shares of the company’s stock were exchanged, compared to its average volume of 163,212. Biolase, Inc. has a 12 month low of $0.28 and a 12 month high of $1.90.
Separately, ValuEngine raised shares of Biolase from a “sell” rating to a “hold” rating in a report on Monday, October 2nd.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2017/12/08/biolase-inc-biol-major-shareholder-larry-n-feinberg-acquires-12545615-shares.html.
Biolase Company Profile
BIOLASE, Inc (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers.
Receive News & Ratings for Biolase Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biolase Inc. and related companies with MarketBeat.com's FREE daily email newsletter.